Logo image of ABVC

ABVC BIOPHARMA INC (ABVC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABVC - US00091F3047 - Common Stock

2.19 USD
+0.15 (+7.35%)
Last: 12/19/2025, 8:26:53 PM
Fundamental Rating

1

Taking everything into account, ABVC scores 1 out of 10 in our fundamental rating. ABVC was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of ABVC have multiple concerns. ABVC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ABVC had negative earnings in the past year.
In the past year ABVC has reported a negative cash flow from operations.
ABVC had negative earnings in each of the past 5 years.
In the past 5 years ABVC always reported negative operating cash flow.
ABVC Yearly Net Income VS EBIT VS OCF VS FCFABVC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

ABVC has a better Return On Assets (-19.44%) than 76.88% of its industry peers.
ABVC has a better Return On Equity (-34.14%) than 72.93% of its industry peers.
Industry RankSector Rank
ROA -19.44%
ROE -34.14%
ROIC N/A
ROA(3y)-110.53%
ROA(5y)-101.93%
ROE(3y)-476.9%
ROE(5y)-372.11%
ROIC(3y)N/A
ROIC(5y)N/A
ABVC Yearly ROA, ROE, ROICABVC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K

1.3 Margins

The Gross Margin of ABVC (63.76%) is better than 79.70% of its industry peers.
ABVC's Gross Margin has been stable in the last couple of years.
ABVC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.89%
GM growth 5Y0.55%
ABVC Yearly Profit, Operating, Gross MarginsABVC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

1

2. Health

2.1 Basic Checks

ABVC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABVC has more shares outstanding
Compared to 5 years ago, ABVC has more shares outstanding
Compared to 1 year ago, ABVC has a worse debt to assets ratio.
ABVC Yearly Shares OutstandingABVC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ABVC Yearly Total Debt VS Total AssetsABVC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -2.14, we must say that ABVC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.14, ABVC perfoms like the industry average, outperforming 48.87% of the companies in the same industry.
A Debt/Equity ratio of 0.07 indicates that ABVC is not too dependend on debt financing.
ABVC's Debt to Equity ratio of 0.07 is on the low side compared to the rest of the industry. ABVC is outperformed by 62.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -2.14
ROIC/WACCN/A
WACC8.55%
ABVC Yearly LT Debt VS Equity VS FCFABVC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

ABVC has a Current Ratio of 0.63. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
ABVC has a worse Current ratio (0.63) than 91.17% of its industry peers.
ABVC has a Quick Ratio of 0.63. This is a bad value and indicates that ABVC is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.62, ABVC is doing worse than 90.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.62
ABVC Yearly Current Assets VS Current LiabilitesABVC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.08% over the past year.
The Revenue has grown by 56.53% in the past year. This is a very strong growth!
Measured over the past years, ABVC shows a decrease in Revenue. The Revenue has been decreasing by -6.15% on average per year.
EPS 1Y (TTM)77.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-168%
Revenue 1Y (TTM)56.53%
Revenue growth 3Y12.28%
Revenue growth 5Y-6.15%
Sales Q2Q%104.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABVC Yearly Revenue VS EstimatesABVC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
ABVC Yearly EPS VS EstimatesABVC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABVC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABVC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVC Price Earnings VS Forward Price EarningsABVC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVC Per share dataABVC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABVC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ABVC BIOPHARMA INC

NASDAQ:ABVC (12/19/2025, 8:26:53 PM)

2.19

+0.15 (+7.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03
Earnings (Next)04-13 2026-04-13/amc
Inst Owners3.23%
Inst Owner Change113.77%
Ins Owners7.95%
Ins Owner Change0%
Market Cap53.22M
Revenue(TTM)798.00K
Net Income(TTM)-4.12M
Analysts43.33
Price TargetN/A
Short Float %1.75%
Short Ratio4.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 66.69
P/FCF N/A
P/OCF N/A
P/B 4.41
P/tB 4.41
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.03
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.44%
ROE -34.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.76%
FCFM N/A
ROA(3y)-110.53%
ROA(5y)-101.93%
ROE(3y)-476.9%
ROE(5y)-372.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.89%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.62
Altman-Z -2.14
F-Score5
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)224.8%
Cap/Depr(5y)N/A
Cap/Sales(3y)8.76%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-168%
EPS Next Y-4.55%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)56.53%
Revenue growth 3Y12.28%
Revenue growth 5Y-6.15%
Sales Q2Q%104.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.23%
OCF growth 3YN/A
OCF growth 5YN/A

ABVC BIOPHARMA INC / ABVC FAQ

Can you provide the ChartMill fundamental rating for ABVC BIOPHARMA INC?

ChartMill assigns a fundamental rating of 1 / 10 to ABVC.


What is the valuation status for ABVC stock?

ChartMill assigns a valuation rating of 0 / 10 to ABVC BIOPHARMA INC (ABVC). This can be considered as Overvalued.


How profitable is ABVC BIOPHARMA INC (ABVC) stock?

ABVC BIOPHARMA INC (ABVC) has a profitability rating of 2 / 10.


How financially healthy is ABVC BIOPHARMA INC?

The financial health rating of ABVC BIOPHARMA INC (ABVC) is 1 / 10.